Get started
Live feed
·
PRReleasevia Quantisnow
Cellectar Biosciences Inc. logo

Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131

ByQuantisnow·Wall Street's wire, on your screen.
Stocks in this Quantisnow insight
Quantisnow market dataNASDAQ
Cellectar Biosciences Inc. logo
CLRB
Cellectar Biosciences Inc.
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Follow CLRBFull CLRB profile on Quantisnow

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CLRB (Cellectar Biosciences Inc.) and more on Quantisnow.